Clementia Pharmaceuticals Inc (CMTA) Receives $24.80 Consensus Target Price from Brokerages

Clementia Pharmaceuticals Inc (NASDAQ:CMTA) has earned a consensus recommendation of “Buy” from the eight ratings firms that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $24.80.

Several research analysts have recently commented on the company. Zacks Investment Research upgraded Clementia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $29.00 target price for the company in a research report on Friday, March 1st. ValuEngine upgraded Clementia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, February 25th. Svb Leerink lowered Clementia Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $26.00 target price for the company. in a research report on Tuesday, February 26th. Robert W. Baird lowered Clementia Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research report on Monday, March 4th. Finally, Bloom Burton lowered Clementia Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 26th.

A number of large investors have recently added to or reduced their stakes in the stock. Opaleye Management Inc. boosted its position in Clementia Pharmaceuticals by 0.8% during the 4th quarter. Opaleye Management Inc. now owns 150,000 shares of the company’s stock valued at $1,764,000 after purchasing an additional 1,168 shares during the period. Northern Trust Corp boosted its position in Clementia Pharmaceuticals by 16.8% during the 4th quarter. Northern Trust Corp now owns 16,211 shares of the company’s stock valued at $191,000 after purchasing an additional 2,335 shares during the period. Trexquant Investment LP acquired a new position in Clementia Pharmaceuticals during the 3rd quarter valued at approximately $126,000. Geode Capital Management LLC boosted its position in Clementia Pharmaceuticals by 90.6% during the 4th quarter. Geode Capital Management LLC now owns 40,638 shares of the company’s stock valued at $477,000 after purchasing an additional 19,317 shares during the period. Finally, Millennium Management LLC acquired a new position in Clementia Pharmaceuticals during the 4th quarter valued at approximately $292,000. Institutional investors and hedge funds own 78.72% of the company’s stock.

Shares of CMTA opened at $26.11 on Friday. The company has a market capitalization of $993.34 million, a PE ratio of -3.29 and a beta of 0.64. Clementia Pharmaceuticals has a 52 week low of $8.10 and a 52 week high of $26.58.

About Clementia Pharmaceuticals

Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.

Read More: The components of the Stochastic Momentum Index

Analyst Recommendations for Clementia Pharmaceuticals (NASDAQ:CMTA)

Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.